Monoclonal antibodies to the myeloid stem cells: Therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate

Leukemia

Volumn 14, Issue 3, 2000, Pages 474-475

  Bernstein, I D ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

AML; Calicheamicin immunoconjugate; CD33

Indexed keywords

ANTIBODY CONJUGATE; CALICHEAMICIN; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW SUPPRESSION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEVER; HEMATOPOIETIC STEM CELL; HUMAN; LIVER DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0034050268     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401663     Document Type: Conference Paper

References (10)

1. Bernstein ID, Singer JW, Smith FO et al. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood 1992; 79: 1811-1816.
2. Singer JW, Bernstein ID, Davis PC, Walters TR, Raskind WH, Fialkow PJ. The effect of long-term marrow culture on the origin of colony-forming cells in acute myeloblastic leukemia: studies of two patients heterozygous for glucose-6-phosphate dehydrogenase. Leukemia 1988; 2: 148-152.
3. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, Dow LW, Najfeld V, Veith R. Clonal development, stem-cell differentiation, and clinical remissions in acute non-lymphocytic leukemia. New Engl J Med 1987; 317: 468-473.
4. Fialkow PJ, Jacobson RJ, Singer JW, Sacher RA, McCuffin RW, Neefe JR. Philadelphia chromosome (Ph1)-negative chronic myelogenous leukemia (CML): a clonal disease with origin in a multipotent stem cell. Blood 1980; 56: 70-73.
5. Anastasi J, Feng J, Dickstein JI et al. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. Leukemia 1996; 10: 795-802.
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 1997; 3: 730-737.
7. Head DR. Revised classification of acute myeloid leukemia. Leukemia 1996; 10: 1826-1831.
8. Appelbaum FR, Matthews DC, Eary JF et al. The use of radio-labeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54: 829-833.
9. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93: 3678-3684.
10. Sievers E, Larson RA, Estey E, Stadtmauer EA, Roy D-CC, Spielberger R, Tarantolo S, Berger MS, Eten C, Manley L, Bernstein I, Appelbaum F. Preliminary results of the efficacy and safety of CMA-676 in patients with AML in first relapse. Proc Am Soc Clin Oncol 1999; 18: 7a (Abstr.).